IDH1 and central nervous system cancer: Based on data of the abovementioned previous studies, a randomized, placebo-controlled phase III trial has been designed with the aim to investigate the efficacy of AG-881 in patients with residual or recurrent non-enhancing IDH1 or 2 mutated grade 2 glioma (INDIGO-trial, NCT04164901).